Search

The David J Apple International Laboratory for Ocular Pathology – a legacy of pioneering IOL research

David Apple and Gerd Auffarth. The Apple Lab at the David J Apple Center for Vision Research in Heidelberg is a thriving international laboratory for research into intraocular devices. The lab continues the work of David J Apple, a world-renowned...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Ophthalmic Aid to Eastern Europe (OAEE)

Peter Cackett, Tim ffytche and Dr Irina Gout reflect on historic ophthalmic aid sent to Eastern Europe. This article was written prior to the horrific events in Ukraine. An appeal for funds and equipment may be made by OAEE later...

See sweet to C-suite: Peter Holland

See also - See sweet to C-suite: Imran Rahman In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part One: David speaks...

Ophthalmic mentors: In conversation with Professor Harminder Dua

In the first of a series of interviews with key figures in the world of ophthalmology, Eye News speaks to Professor Harminder Dua about the future of clinical academia, his recent College presidency and Dua’s Layer. Professor Harminder Dua is...

Strengthening the signal: Advancing oculomics research for systemic health insights

Oculomics, the study of how ocular structure reflects systemic health, is poised to become an integral tool for predicting, triaging, and diagnosing a wide range of diseases. By analysing data from the eye, particularly the retina, healthcare providers can gain...

Retinoblastoma, CureAll and the role of global clinical, capacity strengthening and research networks

Retinoblastoma (Rb), a rare childhood eye cancer, presents a particularly compelling example of how global health partnerships can operate at the intersection of different medical disciplines, in this case: ophthalmology, oncology and public health. This article places the work of...

Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals

Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup

Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...